GlaxoSmithKline related Press Releases

GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 -- Read more...

GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more...

GlaxoSmithKline (GSK) and Santaris Pharma Enter Global R&D Alliance; Santaris Could Receive in Excess of $700 Million Upfront Wednesday December 19, 2007, London, UK & Copenhagen, Denmark -- Read more...

GlaxoSmithKline announces data on Tykerb ® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases Data on abstract 6076 embargoed until Sunday 16 December Read more...

GlaxoSmithKline Receives FDA 'Complete Response' Letter; Cervical Cancer Vaccine Hit by Delay PHILADELPHIA, Dec. 17 -- GlaxoSmithKline announced today that it has received a complete response letter Read more...

GlaxoSmithKline presents innovative neuroscience pipeline Issued on Thursday 13 December 2007 - LSE announcement - GlaxoSmithKline (GSK) plc today presented an overview of its neuroscience portfolio Read more...

GlaxoSmithKline responds to JAMA article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 11 December 2007 - The following is GlaxoSmithKline’s [NYSE: Read more...

GLAXOSMITHKLINE AND GALAPAGOS ENTER STRATEGIC ALLIANCE TO DEVELOP NOVEL ANTIBACTERIALS AND ANTIVIRALS Issued - Monday 10 December 2007, London, UK & Mechelen, Belgium * Discovery and development Read more...

GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance to develop cancer stem cell antibody therapeutics Issued – Monday 10 December 2007, London, UK, Philadelphia, PA and Redwood Read more...

Synta Receives $80 Million Upfront Payment from GlaxoSmithKline Payment Received Following Expiration of Hart-Scott-Rodino Waiting Period LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Read more...